Evaluation of Compatibility and Stability of Compounded Otic Solutions Containing Enrofloxacin Over a 20‐Day Period
- 24 May 2026
- journal article
- Published by Wiley in Veterinary Dermatology
- Vol. 37 (4) , 541-548
Abstract
Background: Compounded otic solutions containing enrofloxacin are commonly used in the management of otitis. Hypothesis/Objectives: The study objective was to evaluate the compatibility and stability of enrofloxacin in compounded otic solutions, as determined by physical changes and quantitated strength. Materials and Methods: Twelve solutions containing 100 mg/mL enrofloxacin (Baytril 100; Elanco) or 22.7 mg/mL enrofloxacin (Baytril; Elanco) were quantitatively analysed on Day (D)0, D10, D15, and D20. Both concentrations of enrofloxacin were combined with sterile water (Hospira), tris‐EDTA (TrizEDTA; Dechra), sterile water and 4 mg/mL dexamethasone sodium phosphate (dexamethasone, Dexium‐SP; Bimeda), tris‐EDTA and dexamethasone, tris‐EDTA with 0.15% ketoconazole (TrizULTRA Keto; Dechra) and dexamethasone, and 1% miconazole nitrate lotion (Covetrus) and dexamethasone. Gross and microscopic evaluation, pH, and temperature were used to assess physical compatibility. Mass spectrometry was used to evaluate precipitate. High‐performance liquid chromatography was used to quantitate drug concentration, indicating strength. Initial separation of ingredients indicating lack of homogenous mixing, immediate precipitate formation, and an exothermic reaction deterred drug strength measurement in solutions containing an antifungal. Results: On D10, in solutions containing tris‐EDTA, average enrofloxacin concentration decreased 25.4% with 100 mg/mL enrofloxacin, 29.3% with 100 mg/mL enrofloxacin and dexamethasone, 45.6% with 22.7 mg/mL enrofloxacin, and 49.8% with 22.7 mg/mL enrofloxacin and dexamethasone. Precipitate formed in all solutions containing tris‐EDTA and filtration of the precipitate did not impact the measured enrofloxacin concentration. Compatibility and stability of enrofloxacin were verified in all solutions containing sterile water. Conclusions and Clinical Relevance: Clinical use of solutions containing enrofloxacin combined with tris‐EDTA or an antifungal is injudicious owing to incompatibility and instability.Keywords
Funding Information
- College of Veterinary Medicine, Auburn University
This publication has 16 references indexed in Scilit:
- The stability and in vitro antibacterial efficacy of enrofloxacin and gentamicin solutions against Staphylococcus pseudintermedius over 28 daysVeterinary Dermatology, 2022
- Rapid and simultaneous determination of dexamethasone and dexamethasone sodium phosphate using HPLC-UV: Application in microneedle-assisted skin permeation and deposition studiesJournal of Chromatography B, 2021
- Preliminary study of the stability of dexamethasone when added to commercial veterinary ear cleaners over a 90 day periodVeterinary Dermatology, 2021
- Ciprofloxacin/dexamethasone precipitate formation in the ear canal of a paediatric patientBMJ Case Reports, 2020
- In vitro antimicrobial activity of topical otological antimicrobials and Tris‐EDTA against resistant Staphylococcus pseudintermedius and Pseudomonas aeruginosa isolates from dogsVeterinary Dermatology, 2019
- Tris–EDTA significantly enhances antibiotic efficacy against multidrug‐resistant Pseudomonas aeruginosa in vitroVeterinary Dermatology, 2013
- Determination of enrofloxacin stability and in vitro efficacy against Staphylococcus pseudintermedius and Pseudomonas aeruginosa in four ear cleaner solutions over a 28 day periodVeterinary Dermatology, 2011
- Medical therapy of otitis externa and otitis mediaVeterinary Clinics of North America: Small Animal Practice, 2004
- A New Approach to HPLC Analysis of Medicinal SuspensionsPharmaceutical Chemistry Journal, 2001
- The use of fluoroquinolones in veterinary dermatologyVeterinary Dermatology, 1999